 Controlled release formulation |
| What is claimed is: 1. In a controlled release angiotensin converting enzyme inhibitor formulation ... |
|
| Formulations providing three distinct releases |
| We claim: 1. A therapeutic composition for oral administration consisting essentially of a ... |
|
| Floating sustained release therapeutic compositions |
| OF THE INVENTION According to the present invention, therapeutic dosage forms have now been ... |
|
| Solid oral dosage forms of ifosfamide |
| OF PREFERRED EMBODIMENTS The invention is illustrated by the following examples: EXAMPLE 1 I... |
|
| [(benzodioxan, benzofuran or benzopyran) alkylamino] alkyl substituted guanidines |
| We claim: 1. A compound of the formula: ##STR259## a pharmaceutically acceptable acid addition salt ... |
|
| Methods for treating dermatitis using descarboethoxyloratadine |
| OF THE INVENTION The present invention encompasses a method of treating allergic asthma in a human ... |
|
| Fat emulsions containing isocarbacyclin |
| What is claimed is: 1. A pharmaceutical prostaglandin emulsion comprising: a mixture of vegetable ... |
|
| Dermal pharmaceutical preparations |
| OF THE INVENTION The support which can be used in the present invention functions to retain a ... |
|
| Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
| We claim: 1. A compound selected from the group consisting of iminodiacid compounds having the ... |
|
|
***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST*** *** NO IMAGES AVAILABLE*** Compositions, methods and devices for the transdermal delivery of drugs
| Details |
Inventors: Schmirler, Dennis Lee; Portman, Edward Malcolm; Christensen, Michael S.;
Assignee:
Primary Examiner: Clardy; S. Mark
Assistant Examiner: Shelborne; Kathryne E.
Attorney, Agent or Firm: Andrus, Sceales, Starke & Sawall, LLP
The present invention is directed to compositions, and methods for the delivery of drugs. Devices for the transdermal delivery of drugs are also provided. Specifically, the present invention relates to hydrogel compositions comprising water and a base mixture, in which the base mixture comprises: (i) a gelling agent consisting of methycellulose or at least one natural gum, or a mixture thereof; (ii) at least one natural gum: (iii) glucose; (iv) propylparaben; (v) methyl paraben; and (vi) sodium chloride. The compositions may further comprise pectin, glycolic, alcoholic or oil-based additives, a coloring, fragrance, or other pharmaceutically acceptable additive. The compositions may further comprise substituted ureas of the formula R--NH--CO--NH.sub.2 such as butylurea. The compositions may further comprise drugs such as hormones selected from progesterone, progestin, estrogen and testosterone. Methods for the treatment of disorders responsive to hormone therapy are also provided. |
|
DETAILED DESCRIPTION OF THE INVENTION The present invention provides compositions comprising (i) a gelling agent consisting of methylcellulose or at least one natural gum, or a mixture thereof; (ii) at least one natural gum; (iii) glucose; (iv) propylparaben; (v) methyl paraben; and (vi) sodium chloride.
The compositions of the present invention may further comprise a glycolic, alcoholic or oil-based additive.
Examples of the glycolic, alcoholic, or oil-based additives that may be used in the compositions of the present invention include, but are not limited to propylene glycol, glycerin, mineral oil, corn oil, bran oil, rice oil, soy oil, ethylene glycol, xylene and alcohols such as ethyl alcohol.
A preferred additive is propylene glycol.
The compositions may further comprise coloring, fragrance or other pharmaceutically acceptable additives.
The compositions of the present invention may also comprise pectin.
In a preferred embodiment, compositions of the present invention consist essentially of methyl cellulose, a natural gum selected from the xanthan and guar gunms, glucose, propyl paraben, methyl paraben, sodium chloride and pectin.
Preferably, compositions of the present invention comprise 50-80% (by weight) methyl cellulose, 15-25% of a natural gum selected from the xanthan and guar gums, 3-7% glucose, 2-3.
5% propylparaben, 1.
5-3% methylparaben, 1-3% sodium chloride and 0.
75-3.
5% pectin.
Even more preferably, the compositions comprise about 63% methylcellulose, about 21% guar gum, about 5% glucose, about 3.
5% propylparaben, about 3% methyl paraben, about 3% pectin and about 1.
5% sodium chloride.
In specific embodiments, drugs are included in the compositions of the present invention.
In a preferred embodiment, the compositions of the present invention further comprise a substituted urea of the formula R--NH--CO--NH.
sub.
2 wherein R is hydrogen, hydroxyl, or a lower alkyl having from 1 to 8 carbon atoms selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl and octyl
|
| Related patents |
|
|
Treatment of sexual dysfunction in certain patient groups
OF THE INVENTION The present invention relates to methods for the treatment of sexual dysfunction in males and females (including but not limited to erectile ...
|
|
|
Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
This invention is therefore aimed at solving the above-mentioned shortcoming of adenosinergic approaches, while obtaining either analgesic (anesthetic) or protective ...
|
|
|
Oil composition
What is claimed is: 1. An oil composition, comprising about 0.1 to 59.8% by weight of a triglyceride, about 40 to 99.7% by weight of a diglyceride, about 0.1 to 10% by ...
|
|
|
Blocking agents of EDRF effect or formation for the treatment of shock
We claim: 1. A therapeutical composition of matter for the treatment by perfusion of shock states comprising as an essential ingredient therein an effective amount of a ...
|
|
|
Use of polyamines as ionic-channel regulating agents
OF THE PREFERRED EMBODIMENTS The disclosure of any and all cited documents including literature and patent application is incorporated by reference in its entirety. It ...
|
|
|
Inhibitor of ceramidase
It is a general object of the invention to provide a method of selecting compounds that cause intracellular accumulation of ceramide. It is a specific object of the ...
|
|
|
Treatment of bone disorders with adrenomedullin
OF THE INVENTION It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following ...
|
|
|
99MTC(III) myocardial imaging agents and method of use
OF THE INVENTION The technetium compounds of the present invention which have been found most useful as myocardial imaging agents in humans comprise hexadentate ...
|
|
|
1,4-dihydro-4-oxo-3-quinoline derivatives as selectively toxic mammalian antibacterial agents
OF THE INVENTION Compounds of the formula I may be prepared as illustrated in the following reaction scheme. ##STR6## Referring to the above reaction scheme, compounds ...
|
|
|
Vaginal sponge delivery system
These and other objects of the invention are achieved in a product which broadly comprises (a) a sealed, air-tight package, enclosing therein (b) a sponge impregnated ...
|
|
|
Vasodialators 
